Serum Bcl-2 Levels in Patients with β-Thalassemia Minor:
A Pilot Study

β-Talasemi Minörlü Hastalarda Serum Bcl-2 Düzeyleri:
Pilot Çalışma

İrfan Yavaşoğlu1, Gökhan Sargin2, Gürhan Kadıköylü1, Ashhan Karul3, Zahit Bolaman1

1Adnan Menderes University Faculty of Medicine, Division of Hematology, Aydın, Turkey
2Adnan Menderes University Faculty of Medicine, Department of Internal Medicine, Aydın, Turkey
3Adnan Menderes University Faculty of Medicine, Department of Biochemistry, Aydın, Turkey

Abstract:

Objective: Anti-apoptotic proteins such as Bcl-2 and Bcl-xL may play a role in the survival of erythroid progenitor cells. Information about these proteins in patients with β-thalassemia minor is limited. We aimed to determine the levels of serum Bcl-2 in patients with β-thalassemia minor.

Materials and Methods: Ninety-seven patients (60 females and 37 males with mean age of 29±21 years) with β-thalassemia minor were enrolled in this study. The diagnosis of β-thalassemia minor was based on whole blood counts, family history, and HbA2 levels estimated by high-performance liquid chromatography. The control group comprised 23 healthy adults (17 females and 6 males with mean age of 58±9 years) without anemia. The levels of serum Bcl-2 were measured by enzyme-linked immunosorbent assay. Mann-Whitney U tests were used in statistical evaluation and p<0.05 was accepted as statistically significant.

Results: Although there was no statistically significant difference between patients with β-thalassemia minor and the control group for the level of serum Bcl-2 (p>0.05), these levels were higher in β-thalassemia minor patients than controls.

Conclusion: There are damaged beta chains in β-thalassemia minor. Therefore, it is expected that premature death of red blood cells may occur due to apoptosis. The mean age of the control group was higher than that of the β-thalassemia minor group; this may be why Bcl-2 levels were higher in the β-thalassemia minor group. It is known that older age constitutes a risk for increased apoptosis. Other proteins (Bad, Bax, etc.) and pathways [CD95 (Fas) ligand] associated with apoptosis should be evaluated in future studies including more patients.

Key Words: β-Thalassemia minor, Bcl-2, Apoptosis
Özet:

Amaç: Bcl-2 ve Bel-xL gibi antiapoptotik proteinler eritroid progenitor hücrelerin yaşam süresinde rol oynayabilir. β-talasemi minor hastalarda bu proteinler ilgili bilgiler sınırlıdır. Biz, β-talasemi minorlı hastalarda serum Bcl-2 düzeylerinin belirlenmesi amaçladık.

Gereç ve Yöntemler: β-talasemi minor tanıni doksan yedi hasta (60 kadın ve 37 erkek, yaş ortalamaları 29±21 yıl) bunça çalıştırda dahil edildi. β-talasemi minor tanı tanesi tam kan sayım, aile öyküsü ve yüksek performanslı sıvı kromatografisine dayanan Hba2 düzeyleri ile konulmuştur. Kontrol grubu anemisi olmayan 23 sağlıklı yetişkin (17 kadın ve 6 erkek, yaş ortalaması 58±9 yıl) idi. Serum Bcl-2 düzeyleri ELISA yöntemi ile ölçüldü. İstatistiksel değerlendirmesinde Mann-Whitney U testi kullanıldı ve p<0.05 istatistiksel olarak anlamli kabul edildi.

Bulgular: Serum Bcl-2 düzeyinde β-talasemi minorlı hastalar ile kontrol grubu arasında istatistiksel olarak anlamli farklılık olmamasına rağmen (p>0.05), β-talasemi minorlı hastalarda bu seviyeler kontrol grubuna göre daha yüksekti.

Sonuç: β-talasemi minorde hasarlı beta zincirleri bulunmaktadır. Bu nedenle, kırmızı kan hücrelerinin erken ölümünün apoptoz nedeniyle olması beklenmektedir. Kontrol grubunun yaş ortalaması talasemi taşıyanlarda yüksektir, bundan dolayı Bcl-2 düzeyleri β-talasemi minorde yüksektir olabilir. Ileri yaşın artması apoptoz için bir risk oluşturtuğu bilinmektedir. Bu nedenle, 40 yaş üzerindeki talasemi minorlülerde, kontrole göre Apoptoz ile ilgili diğer protein (Bad, Bax, vb.) ve yolaklar [CD95 (Fas) ligand] hasta sayısının daha fazla olduğu çalışmalarla değerlendirilmelidir.

Anahtar Sözcükler: β-Talasemi minor, Bcl-2, Apoptoz

**Introduction**

Translations or mutations of mRNA lead to a deficiency of globin synthesis and thus cause thalassemia syndromes [1]. Thalassemia syndromes are inherited disorders that occur as a result of abnormal synthesis of α/β-globin. Cytoplasmic inclusion bodies (including unpaired globin molecules) damage red blood cells. As a result, the life span of erythrocytes is shortened [1,2].

Cell death is regulated by many intra- and extracellular signals. The ratio of anti-apoptotic molecules (Bcl-xl, Mcl-1, Bcl-w, A1, etc.) to apoptotic molecules (Bax, Bak, Bik, Bid, etc.) determines the future of the cell [3]. The Bcl-2 proto-oncogene is located on chromosome 18 and inhibits the apoptotic pathway. Bcl-2 is an important molecule in the early period of cell transformation [3,4].

In recent years, some studies have been published about Bcl-2 genes to predict their role in the development of many solid tumors. However, there are few studies about the expression of Bcl-2 in patients with β-thalassemia minor [5].

In this study, we aimed to determine the levels of serum Bcl-2 in patients with β-thalassemia minor.

**Materials and Methods**

Ninety-seven patients (60 females and 37 males with mean age of 29±21 years) with β-thalassemia minor were enrolled in this study. The diagnosis of β-thalassemia minor was based on whole blood counts, family history, and Hba2 levels estimated by high-performance liquid chromatography (Agilent 1100 Series HPLC Value System, Waldbronn, Germany). The control group comprised 23 healthy adults (17 females and 6 males with mean age of 58±9 years) without anemia. The levels of serum Bcl-2 were measured using a commercial enzyme-linked immunosorbent assay kit (BioSource, Cat. No. TMA 0311, Camarillo, CA, USA). Age, sex, hemoglobin, hematocrit, mean corpuscular volume (MCV), whole blood cell counts, and serum levels of Bcl-2 were recorded. Venous blood samples were taken under the supervision of medical personnel and were measured with an ADVIA 2120 instrument (Siemens, Erlangen, Germany). Signed informed consent was obtained from all participants. SPSS 15 (SPSS Inc., Chicago, IL, USA) and the Mann-Whitney U test were used in statistical evaluation of data and p<0.05 was accepted as statistically significant.

**Results**

In Table 1, age, hemoglobin, MCV, and serum Bcl-2 levels are given. Although there was no statistically significant difference between patients with β-thalassemia minor and the control group for the level of serum Bcl-2 (p>0.05), levels in β-thalassemia minor patients were higher than in the controls. Bcl-2 levels of the patients with β-thalassemia minor control group are shown by dot-plot distribution in Figure 1. The relationships between age, hemoglobin, and MCV values and serum Bcl-2 levels are shown in Table 2.

We evaluated serum Bcl-2 levels of 22 controls and 27 patients with β-thalassemia minor of over 40 years. Bcl-2 levels were statistically significantly higher among patients than in the control group (p=0.045).

**Discussion**

In this study, we did not find any significant difference in Bcl-2 levels between patients with β-thalassemia minor and controls.
Antia apoptotic proteins (Bcl-2, Bcl-xL, and Mcl-1) are necessary for the survival of erythroid precursor cells [6]. Proteins such as Bax and Bcl-xS trigger apoptosis of erythroid cells. According to some studies, Bcl-2 and Bax genes may be regulated by the p53 gene. If the ratio of anti-apoptotic proteins to pro-apoptotic proteins is more than 1, erythroid cells continue their life span [7]. Additionally, members of the Bcl-2 family may control apoptosis by acting as pro-oxidant agents [8].

Erythropoietin increases Bcl-xL expression in erythroid-CFU colonies [5]. Significantly increased Bcl-xL and Mcl-1 protein levels and the suppression of Bax protein are observed in CD34 (+) cells, induced by erythropoietin or stem cell factor [9]. Myelodysplastic syndrome (MDS) is characterized with ineffective erythropoiesis and increased apoptosis of hematopoietic precursor cells. A correlation was observed with increased proteins associated with Bcl-2, but the mechanism is not yet fully understood [10].

Levels of Bad, Bax, and Bcl-xS were especially higher in patients with MDS-refractory anemia (RA) or RA with ring sideroblasts [10]. Many changes in oncogenes and tumor suppressor genes may have a role in the pathogenesis of many diseases. Bcl-2 is located in the nucleus or membranes of the endoplasmic reticulum, while mitochondria were shown to be in neoplastic cells in B-cell neoplasms with t(14;18). The mechanism of Bcl-2 activation is still unknown; however, increased levels of cytochrome-c as a center of apoptosis may play a role [11]. Hockenbery et al. reported that Bcl-2 inhibits apoptosis by changing mitochondrial functions [12].

Translations or mutations of mRNA lead to deficiency of globin synthesis and thus cause thalassemia syndromes. It was reported in many studies that some cancers may be treated by regulation genes on pre-RNA and mRNA regions. Changes in apoptotic or anti-apoptotic pathways may be a result of genetic modulation [13].

β-Thalassemia is characterized by accelerated apoptosis of erythroid precursor cells. In many studies, limited data were reported about these proteins and genetic mechanisms in patients with thalassemia [2,3,4,5]. Increased synthesis of fetal hemoglobin may improve the symptoms of β-thalassemia. Cytotoxic drugs such as hydroxyurea and cytarabine may affect the synthesis of fetal hemoglobin by stimulating precursor cells [1]. Castaneda et al. determined that short-chain fatty acids [arginine butyrate, sodium α-methylhydrocinnamate, sodium 2,2-dimethylbutyrate, sodium 3,4-(methylenedioxy) cinnamate, 2-(quinazolin-4-ylamino) butanoic acid, and 4-(trifluoromethyl) sulfanyl aniline acetic acid] increased the erythroid-BFU colonies and endogenous fetal globin gene expressions [5]. In addition, anti-apoptotic genes were specifically regulated and Bcl-2 levels were increased by short-chain fatty acids. It is known that increased apoptosis is observed with older age [14].

Cao et al. reported that neutrophils of patients with paroxysmal nocturnal hemoglobinuria expressed apoptosis-related CD95, Bcl-2, and Bax without significant differences from the normal controls [15]. The results of a study by Ismail et al. suggest a more significant role for Bcl-x as an anti-apoptotic regulator in CD34 (+) cells in aplastic anemia than Bcl-2 [16].

The limitations of our study were the existence of an age gap between the 2 groups and a limited number of

**Table 1.** Hemoglobin, mean corpuscular volume, and serum Bcl-2 levels in patients with β-thalassemia minor and the control group.

|                     | β-Thalassemia Minor (n=97) | Control (n=23) | p-Value   |
|---------------------|---------------------------|----------------|-----------|
| **Hemoglobin (g/dL)** |                           |                |           |
| Female (n=60)       | 9.9±1.2                   | 12.6±1.3       | <0.001    |
| Male (n=37)         | 13.1±0.8                  | 15.4±1.4       |           |
| **Mean corpuscular volume (fl)** | 64±8                      | 86±3.4         | <0.001    |
| **Bcl-2 (ng/mL)**   | 34.2±7.6                  | 32.7±13        | >0.05     |

**Figure 1.** Serum Bcl-2 levels with dot-plot distribution.
cases. Moreover, we could not evaluate other anti-apoptotic proteins (Bad, Bax, etc.) or pathways [CD 95 (Fas) ligand] in this study. The control group comprised a small number of patients and the control group comprised 23 healthy adults without anemia. Another limitation of this study is that we did not know the levels of annexin V, cleaved caspase-3, or mRNA regulation of Bcl-2.

In conclusion, there are damaged beta chains in beta-thalassemia minor. Therefore, it is expected that premature death of red blood cells may be due to apoptosis. The mean age of the control group was higher than that of the beta-thalassemia minor patients, which may be the reason for Bcl-2 levels being higher in the beta-thalassemia minor patients. It is known that older age constitutes a risk for increased apoptosis. Other proteins and pathways associated with apoptosis should be evaluated in future studies including larger populations.

Conflict of Interest Statement
The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References
1. Benz EJ. Disorders of hemoglobin. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J (eds). Harrison’s Principles of Internal Medicine, 18th ed. New York, McGraw-Hill, 2012.
2. Quek L, Thein SL. Molecular therapies in beta-thalassaemia. Br J Haematol 2007;136:353-365.
3. Yong J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng TI, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997;275:1129-1132.
4. Hacki J, Egger L, Monney L, Conus S, Rosse T, Fellay I, Borner C. Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2. Oncogene 2000;19:2286-2295.
5. Castaneda S, Boosalis MS, Emery D, Thies A, Faller DV, Perrine SP. Enhancement of growth and survival and alterations in Bcl-famil protein in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives. Blood Cells Mol Dis 2005;35:217-226.
6. Koury MJ, Sawyer ST, Brandt SJ. New insights into erythropoiesis. Curr Opin Hematol 2002;9:93-100.
7. Chao DT, Korsmeyer SJ. Bcl-2 family: regulators of cell death. Annu Rev Immunol 1998;16:395-419.
8. Haddad JJ. On the antioxidant mechanisms of Bcl-2: a retrospective of NF-kB signaling and oxidative stress. Biochem Biophys Res Commun 2004;17:322:355-363.
9. Josefsen D, Myklebust JH, Lomo J, Sioud M, Blomhoff HK, Smeland EB. Differential expression of Bcl-2 homologs in human CD34(+) hematopoietic progenitor cells induced to differentiate into erythroid or granulocytic cells. Stem Cells 2000;18:261-272.
10. Boudard D, Vasselon C, Berthéas MF, Jaubert J, Mounier C, Reynaud J, Viallet A, Chautard S, Guyotat D, Campos L. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am J Hematol 2002;70:115-125.
11. Tsujimoto Y, Gorham J, Cossmann J, Jaffe E, Croce CM. The t (14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985;229:1390-1393.
12. Hockenbery D, Nunez G, Milliman C. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
13. Bauma JA, Kole R. Modulation of RNA splicing as a potential treatment for cancer. Bioeng Bugs 2011;2:125-128.
14. Fulle S, Centurione L, Mancinelli R, Sancilio S, Manzoli FA, Di Pietro R. Stem cell ageing and apoptosis. Curr Pharm Des 2012;18:1694-1717.
15. Cao YR, Shao ZH, Liu H, Zhao MF, He GS, Shi J, Bai J, Fu R, Tu MF, Wang HQ, Xing LM, Cui ZZ, Sun J, Jia HR, Yang TY. Expression of apoptosis-related proteins in bone marrow neutrophils of patients with paroxysmal nocturnal hemoglobinuria. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2003;13:871-884.
16. Ismail M, Gibson FM, Gordon-Smith EC, Rutherford TR. Bcl-2 and Bcl-x expression in the CD34+ cells of aplastic anaemia patients: relationship with increased apoptosis and upregulation of Fas antigen. Br J Haematol 200;113:706-712.